Back to Trials
NCT05711732Recruiting

Busulfan Sample Collection Study

Saladax Biomedical, Inc.

Start Date

2/8/2024

Completion Date

4/30/2027

Summary

Busulfan (Busulfex®) is an alkylating drug used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. Busulfan has wide inter- and intra-patient pharmacokinetic variability resulting in variable exposure leading to increased risk of toxicities or sub-optimal treatment outcomes. Therapeutic drug monitoring of busulfan using patient plasma samples would benefit clinicians by providing the ability to personalize the dose to achieve a target busulfan exposure.

Detailed Description

This protocol is sponsored by Saladax Biomedical, Inc (SBI). The protocol involves the use of sodium heparin plasma sample collected from human subjects receiving intravenous busulfan treatment for the use in the development of a diagnostic test for this drug. A subset of 10 enrolled subject samples will be tested on site using an automated immunoassay MyCareTM Oncology Busulfan Assay Kit manufactured by SBI.

Eligibility Criteria

Age Range: No minimum to No maximum

Inclusion Criteria: 1. Pediatric and adult female or male subjects; 2. Current treatment with intravenous busulfan with documentation of diagnosed malignant hematologic or non-malignant disease condition requiring treatment; 3. Adult participants must be capable of understanding and providing written informed consent, approved by an Institutional Review Board (IRB) prior to the initiation of any screening or study-specific procedures. Participants less than 18 years old must provide written assent with appropriate consent provided by legal guardian, who must be capable of understanding and providing informed consent, per Institutional Review Board (IRB) procedures, prior to the initiation of any screening or study-specific procedures. Exclusion Criteria: 1. Unwilling or unable to follow protocol requirements or to give written informed consent; 2. Patients receiving oral busulfan (e.g., Myleran®) treatment.

Interventions

DIAGNOSTIC_TEST

MyCare Oncology Busulfan Assay Kit

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Subjects Treated With Busulfan

Locations

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Chicago, Illinois 60611

United States

Rutgers Cancer Institute

New Brunswick, New Jersey 08903

United States

The University of Texas MD Anderson Cancer Center

Houston, Texas 77030

United States